Subcutaneous

[키워드] 24 hour 7-point ordinal scale absence addition administration Admission ALT anticipated assigned AST baseline biological parameters candidate Care clinical Clinical research clinical status clinical trial clinician Comorbidity conditions Control control arm control group Coronavirus infections Council COVID 19 COVID-19 COVID-19 infection criteria current D-dimer Day death rate decrease discharge dissemination dose drug Duration early stage Efficacy element ELISA enrolment EudraCT European evaluate exclusion criteria exploratory extracorporeal membrane oxygenation Frame harmonization hospitalisation hospitalised hospitalised patient hyperinflammatory status hypersensitivity Hypothesis identify IL-6 IL-6 levels IL-6 receptor inhibitors IL-6R In-hospital incidence Inclusion inclusion criteria independent Infection Informed inhibitor interstitial pneumonia Intervention intervention group intestinal perforation Invasive mechanical ventilation investigator investigator-initiated lactation Local marker measure mechanical ventilation moderate moderate-severe neutrophil count Non-invasive non-invasive ventilation number number of death objective Open label trial outbreak outcome oxygen Oxygenation pandemic participant pathogen patients treated performed Platelet Pneumonia positive positive RT-PCR Positive test Prednisone Presence Prevent progression protocol random randomisation randomised randomised controlled trial receive recruited recruitment Registered reported requiring supplemental oxygen responsible routine clinical practice RT-PCR SAEs Sample size sarilumab SARS-CoV-2 SARS-COV-2 infection score Sepsis Serious Adverse Event serum Severe COVID-19 Infection single center single dose Spain Standard Standard of care status Study protocol Subcutaneous subcutaneous injection the patient therapy treated Treatment treatment arm treatment with tocilizumab Trial ULN union unit verbal website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter